[HTML][HTML] Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated …

J Corominas, C Garriga, A Prenafeta… - The Lancet Regional …, 2023 - thelancet.com
Background A SARS-CoV-2 protein-based heterodimer vaccine, PHH-1V, has been shown
to be safe and well-tolerated in healthy young adults in a first-in-human, Phase I/IIa study …

Preclinical efficacy, safety, and immunogenicity of PHH-1V, a second-generation COVID-19 vaccine candidate based on a novel recombinant RBD fusion heterodimer …

…, R March, L González, L Madrenas, J Corominas… - BioRxiv, 2021 - biorxiv.org
Since the genetic sequence of SARS-CoV-2 became available in January 2020, new
vaccines have been developed at an unprecedented speed. The current vaccines have been …

[HTML][HTML] A spatial method to calculate small-scale fisheries effort in data poor scenarios

…, M Moreno-Báez, A Giron-Nava, J Corominas… - PLoS …, 2017 - journals.plos.org
To gauge the collateral impacts of fishing we must know where fishing boats operate and how
much they fish. Although small-scale fisheries land approximately the same amount of fish …

[PDF][PDF] Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2

…, L González-González, L Madrenas, J Corominas… - Iscience, 2023 - cell.com
Current COVID-19 vaccines have been associated with a decline in infection rates, prevention
of severe disease, and a decrease in mortality rates. However, SARS-CoV-2 variants are …

[HTML][HTML] Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2

…, G Domenech, B Clotet, J Corominas… - npj Vaccines, 2023 - nature.com
In response to COVID-19 pandemic, we have launched a vaccine development program
against SARS-CoV-2. Here we report the safety, tolerability, and immunogenicity of a …

Clinical experience with brivaracetam in a series of 46 children

…, F Paredes-Carmona, JS Coromina… - Epilepsy & Behavior, 2020 - Elsevier
Objectives The primary objective of the study was to analyze the efficacy of brivaracetam (BRV)
in pediatric patients 12 months after starting treatment. The secondary objective was to …

Safety and Immunogenicity of a Recombinant Protein RBD Fusion Heterodimer Vaccine against SARS-CoV-2: preliminary results of a phase 1-2a dose-escalating …

…, G Domenech, B Clotet, J Corominas… - medRxiv, 2022 - medrxiv.org
Background We report safety, tolerability, and immunogenicity of a recombinant protein RBD-fusion
heterodimeric vaccine against SARS-CoV-2 (PHH-1V). Methods A dose-escalation, …

PREMI JÚLIA COROMINES 2017 2018

J Coromines - Revista Catalana de Psicoanàlisi - raco.cat
… Joan Coromines, germà de Júlia Coromines, ha estat una de les personalitats de més
prestigi lingüístic del país i ell es deia i es feia dir Coromines, no solament pel que fa al seu …

Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial

J Corominas, C Garriga, A Prenafeta, A Moros… - medRxiv, 2024 - medrxiv.org
The HIPRA-HH-2 was a multicentre, randomized, active-controlled, double-blind, non-inferiority
phase IIb clinical trial to compare the immunogenicity and safety of a heterologous …

Aportacions punteres de la Dra. Júlia Corominas a la comprensió de l'autisme

L Viloca - Revista Catalana de Psicoanàlisi, 2011 - raco.cat
Júlia Corominas en el camp de l’autisme i dels processos mentals primaris. J. Corominas
- a partir de Klein, Tustin, Meltzer, Resnik, Ogden, Segal i de la seva experiència en el …